Advertisement


Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial

2015 IASLC World Conference on Lung Cancer

Advertisement

Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).



Related Videos

Lung Cancer

Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).

Lung Cancer
Symptom Management

Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials

Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).

Lung Cancer

Naiyer A. Rizvi, MD, on Immune Checkpoint Inhibitors

Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.

Lung Cancer

James R. Jett, MD, on Screening With Early CDT and CT

James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, this biomarker would increase the detection of early-stage lung cancer (Abstract MINI 12.11).

Lung Cancer

William D. Travis, MD, on Pathology and Genetics of Lung Tumors: 2015 WHO Classification

William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).

Advertisement

Advertisement




Advertisement